• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 29, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New research shows people with PAD could have an omega-3 deficiency

Bioengineer by Bioengineer
March 21, 2019
in Health
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New research shows that people who have PAD also have a low Omega-3 Index

New research published in the March 18th edition of Lipids showed that people who have peripheral artery disease (PAD) have a lower Omega-3 Index compared to those who don’t have the disease.

PAD is a disease that affects the blood vessels outside the heart and brain. Evidence from other studies suggests that omega-3s affect many steps of the atherosclerotic process. More specifically, they improve endothelial function; promote vasodilatation through relaxation of smooth muscle cells; exert antioxidant, anti-inflammatory, and antithrombotic actions; delay development of plaques and increase their stability; and decrease wall stiffening.

Because PAD is essentially atherosclerosis of the leg arteries, researchers in this study believe that patients with PAD may have an omega-3 fatty acid deficiency.

To study the relationship between the Omega-3 Index and PAD, the investigators compared the Omega-3 Index in 145 patients with PAD to 34 controls without PAD.

They found that the Omega-3 Index was significantly lower in the PAD patients than the controls (5% vs 6%). When they controlled for other patient characteristics that might have influenced these findings (like age, smoking, blood pressure, diabetes, drugs, etc.), the Omega-3 Index was still lower in the cases vs. the controls.

In the final analysis, for every 1% unit reduction in the Omega-3 Index, the odds of being a PAD patient increased by 39%, and for every additional pack-year of smoking the odds of being a PAD case increased by 4%.

“It is likely that the lower inflammatory burden associated with a higher Omega-3 Index may be part of the explanation for these results,” said Bill Harris, Ph.D., one of the study’s authors. “Whether long-term use of omega-3 supplements and/or increased consumption of oily fish could prevent the development of PAD should be examined in future studies.”

###

Media Inquiries:

Becky Wright

Marketing & Communications Manager, OmegaQuant

201-675-0197

[email protected]

About OmegaQuant: OmegaQuant is an independent, CLIA-certified lab that offers Omega-3 Index testing to researchers, clinicians and the public and sets the standard for fatty acid testing. OmegaQuant performs fatty acid analysis in Sioux Falls, SD for commercial and academic research collaborators, and for consumers interested in monitoring their nutritional status in both blood and breast milk. Its goal is to offer the highest quality fatty acid analytical services to researchers and to provide simple tests of nutritional status to consumers, with the ultimate purpose of advancing the science and use of omega-3 fatty acids to improve health. Most recently, it opened an additional lab in Brisbane, Australia. It also recently received approval in the EU market and opened a lab in Scotland, officially making the Omega-3 Index an internationally accessible test.

Media Contact
Becky Wright
[email protected]
http://dx.doi.org/10.1002/lipd.12140

Tags: Alternative MedicineCardiologyClinical TrialsDiagnosticsMedicine/HealthNutrition/Nutrients
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Novel Plasma Synuclein Test Advances Parkinson’s Diagnosis

July 29, 2025
blank

Obesity’s Impact on Pancreatic Surgery Outcomes Compared

July 28, 2025

Virion Movement in Sialoglycan-Cleaving Respiratory Viruses

July 28, 2025

Bariatric Surgery’s Impact on Circulating S100A9

July 28, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    54 shares
    Share 22 Tweet 14
  • USF Research Unveils AI Technology for Detecting Early PTSD Indicators in Youth Through Facial Analysis

    42 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    45 shares
    Share 18 Tweet 11
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Novel Plasma Synuclein Test Advances Parkinson’s Diagnosis

Advancing Microbial Risk Assessment Through Detection Technology Evolution

Obesity’s Impact on Pancreatic Surgery Outcomes Compared

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.